Xencor reports smaller-than-expected Q2 loss

Xencor

06/08/2025 21:14

Overview

Xencor Q2 revenue rises to $43.6 mln, beating analyst expectations, per LSEG data

Adjusted EPS loss of $0.41 beats estimates, per LSEG data

Net loss narrows to $30.8 mln from $67.3 mln a year ago

Outlook

Xencor expects to end 2025 with $555-585 mln in cash

Company anticipates funding operations into 2028

Result Drivers

MILESTONE PAYMENTS - Revenue increase driven by $25 mln milestone payment from Incyte for Monjuvi approval

ROYALTY REVENUE - Non-cash royalty revenue from Alexion and Incyte contributed to Q2 revenue

R&D SPENDING - Stable R&D expenses reflect increased spending on XmAb819, XmAb541, and XmAb657, offset by reduced costs from terminated programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$43.60 mln
$21.40 mln (11 Analysts)
Q2 EPS
Beat
-$0.41
-$0.72 (11 Analysts)
Q2 Net Income
-$30.82 mln
Q2 Operating Expenses
$76.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Xencor Inc is $31.00, about 74.4% above its August 5 closing price of $7.95

Press Release: ID:nBw6rd4q4a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)